/stocks — the workspaceLOADING
All GPLB SEC filings, by type → · Earnings date & implied move · Search inside filings
Green Planet Bio Engineering Co. Ltd. (GPLB) is a biological products, (no diagnostic substances) company. Fundamentals from SEC filings; prices are end-of-day.
What’s behind GPLB’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from GPLB’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
A plain-English read on GPLB plus an auto-SWOT — built from GPLB's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate GPLB using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as GPLB tagged it: net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
Projected from GPLB's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentGPLB files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No tracked institution reported a position in GPLB in the latest 13F round.
No lawmaker has disclosed a trade in GPLB under the STOCK Act.
None of the 5 estimators could run on GPLB's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for GPLB. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for GPLB, so sector medians could not fill the gaps.
Every refusal recorded for GPLB → · How often we decline, and why →
No open-market Form 4 buys or sells reported for GPLB in the last ~6 months.
1 of the 1 checks that ran found nothing new for GPLB. 3 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: Aventura, Florida, United States · the company’s charter and its head office are in different states.
Source: the cover page of Green Planet Bio Engineering Co. Ltd.’s 10-Q filed 2026-08-13, on EDGAR. Filings checked 2026-10-21. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works